Abivax To Present Four Abstracts For Obefazimod In Ulcerative Colitis And Preclinical Colon Cancer Model At Digestive Disease Week 2024

5/8/24 4:18:39 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ABVX alert in real time by email

"With four abstracts accepted for presentation at DDW 2024, we look forward to our continued exchange with the IBD community around the emerging clinical profile of obefazimod," said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax. "We are excited to share new preclinical data showing obefazimod's impact in reducing the number of tumors in the azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse model of colitis-associated cancer—data in support of obefazimod's novel mechanism of action."

Get the next $ABVX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABVX

Date	Price Target	Rating	Analyst
7/29/2024	$48.00	Buy	Laidlaw
5/20/2024	$43.00	Buy	BTIG Research
4/29/2024	$42.00	Overweight	Piper Sandler
4/29/2024	$50.00	Buy	Guggenheim
11/14/2023	$15.00	Equal-Weight	Morgan Stanley
11/14/2023	$20.00	Outperform	Leerink Partners

More analyst ratings

$ABVX
Press Releases

Fastest customizable press release news feed in the world

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program ("ATM Program") allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares ("ADS"), each ADS representing one ordinary share, nominal value €0.01 per share
11/19/24 4:30:00 PM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
Abivax presents third quarter 2024 key financial information
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. Abivax provided the following updates on its business and operational goals in press releases published: On July 15, 2024 press release titled "Abivax provides operational and key program update"On August 6, 2024 press rele
11/14/24 4:01:00 PM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn
11/13/24 4:01:00 PM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care

$ABVX
Leadership Updates

Live Leadership Updates

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn
11/13/24 4:01:00 PM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
Abivax Provides Operational and Key Program Update
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-
7/15/24 4:00:00 PM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
PARIS, France, June 4, 2024 – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the "General Meeting"), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the 2023 financial year, the compensation poli
6/4/24 4:10:00 PM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care

Abivax Provides Operational And Key Program Update, Phase 3 ABTECT Trial Evaluating Obefazimod In Moderately To Severely Active Ulcerative Colitis On Track To Complete Enrollment In Early Q1 2025; Cash Position Allows For Runway Into Q4 2025 Through ABTECT 8-Week Induction Top-Line Results
Abivax Provides Operational and Key Program UpdatePhase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-week
7/15/24 4:01:50 PM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the company announced a private offering of $125 million of convertible senior notes. AMC Networks shares dipped 9.4% to $14.24 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Evotec SE (NYSE:EVO) shares fell 7.7% to $4.20 in pre-market trading. Absci Corporation (NASDAQ:ABSI) declined 5.8% to $3.75 in pre-market trading after declining around 9% on Friday. Humacyte, Inc. (NASDAQ:HUMA) fell 5.7% to $6.65 in pre-market trading.
6/17/24 7:41:58 AM ET
$ABSI
$ABVX
$AMCX
$EVO
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Biotechnology: Pharmaceutical Preparations
Cable & Other Pay Television Services
BTIG Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $43
BTIG analyst Julian Harrison initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $43.
5/20/24 7:36:19 AM ET
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care

Abivax To Present Four Abstracts For Obefazimod In Ulcerative Colitis And Preclinical Colon Cancer Model At Digestive Disease Week 2024

Chat with this insight

Recent Analyst Ratings for
$ABVX

$ABVX
Press Releases

Fastest customizable press release news feed in the world

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

$ABVX
SEC Filings

$ABVX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 6-K filed by Abivax SA

SEC Form F-3 filed by Abivax SA

SEC Form 6-K filed by Abivax SA

Amendment: SEC Form SC 13G/A filed by Abivax SA

SEC Form SC 13G filed by Abivax SA

$ABVX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Laidlaw initiated coverage on Abivax SA with a new price target

BTIG Research initiated coverage on Abivax SA with a new price target

Piper Sandler initiated coverage on Abivax SA with a new price target

$ABVX
Leadership Updates

Live Leadership Updates

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Provides Operational and Key Program Update

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

$ABVX
Market Insights

Live Market Insights

Abivax Provides Operational And Key Program Update, Phase 3 ABTECT Trial Evaluating Obefazimod In Moderately To Severely Active Ulcerative Colitis On Track To Complete Enrollment In Early Q1 2025; Cash Position Allows For Runway Into Q4 2025 Through ABTECT 8-Week Induction Top-Line Results

AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BTIG Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $43

Abivax To Present Four Abstracts For Obefazimod In Ulcerative Colitis And Preclinical Colon Cancer Model At Digestive Disease Week 2024

Chat with this insight

Recent Analyst Ratings for $ABVX

$ABVX Press Releases

Fastest customizable press release news feed in the world

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

$ABVX SEC Filings

$ABVX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 6-K filed by Abivax SA

SEC Form F-3 filed by Abivax SA

SEC Form 6-K filed by Abivax SA

Amendment: SEC Form SC 13G/A filed by Abivax SA

SEC Form SC 13G filed by Abivax SA

$ABVX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Laidlaw initiated coverage on Abivax SA with a new price target

BTIG Research initiated coverage on Abivax SA with a new price target

Piper Sandler initiated coverage on Abivax SA with a new price target

$ABVX Leadership Updates

Live Leadership Updates

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Provides Operational and Key Program Update

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

$ABVX Market Insights

Live Market Insights

Abivax Provides Operational And Key Program Update, Phase 3 ABTECT Trial Evaluating Obefazimod In Moderately To Severely Active Ulcerative Colitis On Track To Complete Enrollment In Early Q1 2025; Cash Position Allows For Runway Into Q4 2025 Through ABTECT 8-Week Induction Top-Line Results

AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BTIG Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $43

Recent Analyst Ratings for
$ABVX

$ABVX
Press Releases

$ABVX
SEC Filings

$ABVX
Large Ownership Changes

$ABVX
Analyst Ratings

$ABVX
Leadership Updates

$ABVX
Market Insights